Risk Stratification and Validation of Prostate Specific Antigen Density as Independent Predictor of Progression in Men With Low Risk Prostate Cancer During Active Surveillance

被引:63
作者
Francisco, Ignacio F. San [1 ,4 ]
Werner, Lillian [3 ]
Regan, Meredith M. [3 ]
Garnick, Marc B. [2 ]
Bubley, Glenn [2 ]
DeWolf, William C. [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA
[3] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[4] Pontificia Univ Catolica Chile, Dept Urol, Santiago, Chile
关键词
prostate; prostatic neoplasms; prostate-specific antigen; biopsy; risk; EXPECTANT MANAGEMENT; CURATIVE INTENT; BIOPSY;
D O I
10.1016/j.juro.2010.09.115
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We assessed risk stratification in patients with low grade prostate cancer managed by active surveillance using a 20-core saturation biopsy technique. Materials and Methods: A total of 135 consecutive patients with low risk prostate cancer were prospectively entered in an active surveillance program in a 10-year period. The study entrance requirement and progression definition followed Epstein criteria using only pathological parameters, ie fewer than 3 positive cores, Gleason score 6 or less and 50% or less of any single core involved. All patients were monitored by restaging 20-core saturation biopsy every 12 to 18 months. A total of 120 patients with at least 1 rebiopsy form the basis of this report. Results: Of the cohort 30% progressed during a median of 2.4 years. Three multivariate analyses were performed. The first analysis used variables only at diagnosis biopsy and revealed that prostate specific antigen density greater than 0.08 ng/ml/cc and prostate cancer family history were significant predictors of progression. When combined in a 3-level risk factor score, they were significant (p = 0.003). The second multivariate analysis considered changes in characteristics between diagnosis biopsy and first rebiopsy. Prostate specific antigen velocity along with prostate specific antigen density and family history highly predicted progression according to a 4-level risk factor score (p < 0.0001). The third multivariate analysis validated the previously reported prostate specific antigen density cutoff of 0.08 ng/ml/cc at first rebiopsy as a significant predictor of subsequent progression (HR 3.16, 95% CI 1.12, 8.93; p = 0.03). Conclusions: Risk factor stratification can be used to significantly predict the outcome in patients on active surveillance. Prostate specific antigen density 0.08 ng/ml/cc at first rebiopsy was validated as a significant predictor of subsequent progression.
引用
收藏
页码:471 / 476
页数:6
相关论文
共 17 条
[1]   PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer:: Results from the European randomized study of screening for prostate cancer, Sweden section [J].
Ali, Khatami ;
Gunnar, Aus ;
Jan-Erik, Damber ;
Hans, Lija ;
Par, Lodding ;
Jonas, Hugosson .
INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (01) :170-174
[2]   Expectant management of prostate cancer with curative intent: An update of the Johns Hopkins experience [J].
Carter, H. Ballentine ;
Kettermann, Anna ;
Warlick, Christopher ;
Metter, E. Jeffrey ;
Landis, Patricia ;
Walsh, Patrick C. ;
Epstein, Jonathan I. .
JOURNAL OF UROLOGY, 2007, 178 (06) :2359-2364
[3]   Expectant management of nonpalpable prostate cancer with curative intent: Preliminary results [J].
Carter, HB ;
Walsh, PC ;
Landis, P ;
Epstein, JI .
JOURNAL OF UROLOGY, 2002, 167 (03) :1231-1234
[4]   Pathological Outcomes of Candidates for Active Surveillance of Prostate Cancer [J].
Conti, Simon L. ;
Dall'Era, Marc ;
Fradet, Vincent ;
Cowan, Janet E. ;
Simko, Jeffery ;
Carroll, Peter R. .
JOURNAL OF UROLOGY, 2009, 181 (04) :1628-1633
[5]   Radical Prostatectomy Findings in Patients in Whom Active Surveillance of Prostate Cancer Fails [J].
Duffield, Amy S. ;
Lee, Thomas K. ;
Miyamoto, Hiroshi ;
Carter, H. Ballantine ;
Epstein, Jonathan I. .
JOURNAL OF UROLOGY, 2009, 182 (05) :2274-2278
[6]   PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER [J].
EPSTEIN, JI ;
WALSH, PC ;
CARMICHAEL, M ;
BRENDLER, CB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (05) :368-374
[7]   Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy [J].
Epstein, JI ;
Sanderson, H ;
Carter, HB ;
Scharfstein, DO .
UROLOGY, 2005, 66 (02) :356-360
[8]   Individual prostate biopsy core embedding facilitates maximal tissue representation [J].
Kao, J ;
Upton, M ;
Zhang, P ;
Rosen, S .
JOURNAL OF UROLOGY, 2002, 168 (02) :496-499
[9]   Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer [J].
Klotz, Laurence ;
Zhang, Liying ;
Lam, Adam ;
Nam, Robert ;
Mamedov, Alexandre ;
Loblaw, Andrew .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :126-131
[10]  
National Comprehensive Cancer Network, 2010, PROST CANC GUID V2